Today's Health Winners and Losers
Shares of Immucor (BLUD) were among the best-performing health-related stocks Thursday, rising 7% after the company posted better-than-expected third-quarter results.
The company, which sells reagents and systems used to identify the properties of blood prior to a transfusion, earned $11.7 million, or 25 cents a share, on revenue of $47.1 million. Analysts polled by Thomson First Call expected earnings of 23 cents a share and revenue of $47 million. During the year-earlier period, Immucor earned $6.5 million, or 14 cents a share, on revenue of $38 million. The company attributed the year-over-year sales jump to price increases.
Immucor sees fiscal 2006 earnings of $38.3 million to $40.6 million, or 81 cents to 85 cents a share. The company predicts revenue of $180 million to $183 million, while gross margin is expected to range from 65% to 66%. Analysts project earnings of 84 cents a share and revenue of $182.1 million. Immucor shares recently were up $2.14 to $30.90.
Urologix (ULGX) shares jumped 30% after the Food and Drug Administration approved the company's new CoolWave control unit, which is used in the treatment of benign prostatic hyperplasia. The medical-device maker plans to launch the product between July and September. "The new user interface and increased processing power of CoolWave allow our urologists to set customized treatments for their BPH patients, including those with small glands and symptomatic BHP, while maintaining the ease of use they are accustomed to," Urologix said. Shares were up $1 to $4.36.Shares of Aastrom Biosciences (ASTM) fell 6% after the stem-cell company said it plans to sell 15.9 million shares of stock at $1.60 apiece, raising about $25.5 million. The price represents a 10% discount to Wednesday's closing price of $1.78. The sale is expected to close during the next few days, the company said. Shares were down 11 cents to $1.67.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV